Sequenom CMM's MaterniT21 PLUS LDT Now Reporting On Gender-Specific Chromosomal Abnormalities

     Sequenom CMM's MaterniT21 PLUS LDT Now Reporting On Gender-Specific
                          Chromosomal Abnormalities

PR Newswire

SAN DIEGO, Feb. 4, 2013

SAN DIEGO, Feb. 4, 2013 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life
sciences company providing innovative diagnostic testing and genetic analysis
solutions, announced today that the MaterniT21™ PLUS laboratory-developed test
(LDT) available exclusively through Sequenom Center for Molecular Medicine
(Sequenom CMM) will now report as additional findings the presence of certain
fetal sex chromosomal aneuploidies, in addition to its identification of
autosomal aneuploidies for chromosome 21 (associated with Down syndrome),
chromosome 18 (associated with Edwards syndrome), and chromosome 13
(associated with Patau syndrome). Reporting of these sex aneuploidies will
begin for samples received as of Monday, February 4, 2013.

The test will report on the presence of four rare aneuploidies involving an
abnormal number of X or Y chromosomes, including female syndromes 45,X (Turner
Syndrome) and 47,XXX (Triple X Syndrome), and male syndromes 47,XXY
(Klinefelter Syndrome) and 47,XYY. Results of the blinded clinical validation
study set have been submitted for publication in a peer-reviewed journal.

"Sex chromosome abnormalities may be recognized at birth, as part of the
spectrum of less severe chromosome abnormalities. They can also be found in
adults, many being incidentally discovered in the course of evaluating
patients for infertility or endocrine problems. Identifying these conditions
through the MaterniT21 PLUS test will allow the health care provider and
patient to discuss the medical issues associated with these conditions as well
as to develop both short- and long-term care plans," said Allan Bombard, MD,
Sequenom's Chief Medical Officer.

The MaterniT21 PLUS test analyzes the relative amount of 21, 18, 13, as well
as X and Y chromosomal material in cell-free DNA. The test is intended for
use in pregnant women at increased risk for fetal aneuploidy and can be used
as early as 10 weeks' gestation. Estimates suggest there are about 750,000
pregnancies at high risk for fetal aneuploidy each year in the United States.
The MaterniT21 PLUS test is available exclusively through the Sequenom Center
for Molecular Medicine (Sequenom CMM) as a testing service provided to
physicians. To learn more about the test, please visit

About Sequenom

Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to
improving healthcare through revolutionary genetic analysis solutions.
Sequenom develops innovative technology, products and diagnostic tests that
target and serve discovery and clinical research, and molecular diagnostics
markets. The company was founded in 1994 and is headquartered in San Diego,
California. Sequenom maintains a Web site at to which
Sequenom regularly posts copies of its press releases as well as additional
information about Sequenom. Interested persons can subscribe on the Sequenom
Web site to email alerts or RSS feeds that are sent automatically when
Sequenom issues press releases, files its reports with the Securities and
Exchange Commission or posts certain other information to the Web site.

About Sequenom CMM

Sequenom Center for Molecular Medicine® (Sequenom CMM), a CAP accredited and
CLIA-certified molecular diagnostics laboratory, has developed a broad range
of laboratory tests with a focus on prenatal and ophthalmological diseases and
conditions. Branded under the name SensiGene™, MaterniT21™ PLUS, and
RetnaGene™, these molecular genetic laboratory tests provide early patient
management information for obstetricians, geneticists and maternal fetal
medicine specialists. Sequenom CMM is changing the landscape in genetic
disorder diagnostics using proprietary cutting edge technologies.

Forward-Looking Statement

Except for the historical information contained herein, the matters set forth
in this press release, including statements regarding the expected publication
and timing thereof of the validation data for the fetal sex chromosomal
aneuploidies, the expected date of February 4, 2013 for reporting fetal sex
chromosomal aneuploidies, the impact, benefits, and effect of identifying
fetal sex chromosomal aneuploidies on patient care and planning, the Company's
commitment to improving healthcare through revolutionary genetic analysis
solutions, and Sequenom CMM changing the landscape in genetic disorder
diagnostics, are forward-looking statements within the meaning of the "safe
harbor" provisions of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements are subject to risks and uncertainties that
may cause actual results to differ materially, including the risks and
uncertainties associated with market demand for and acceptance and use of
technology and tests such as the MaterniT21 PLUS test, reliance upon the
collaborative efforts of other parties such as, without limitation, healthcare
providers, international distributors and licensees, the Company or third
parties obtaining or maintaining regulatory approvals that impact the
Company's business, government regulation particularly with respect to
diagnostic products and laboratory developed tests, publication processes, the
performance of designed product enhancements, the Company's ability to develop
and commercialize technologies and products, particularly new technologies
such as noninvasive prenatal diagnostics, laboratory developed tests, and
genetic analysis platforms, the Company's financial position, the Company's
ability to manage its existing cash resources or raise additional cash
resources, competition, intellectual property protection and intellectual
property rights of others, litigation involving the Company, and other risks
detailed from time to time in the Company's most recently filed Quarterly
Report on Form 10-Q for the quarter ended September 30, 2012 and its Annual
Report on Form 10-K for the year ended December 31, 2011, and other documents
subsequently filed with or furnished to the Securities and Exchange
Commission. These forward-looking statements are based on current information
that may change and you are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date of this press
release. All forward-looking statements are qualified in their entirety by
this cautionary statement, and the Company undertakes no obligation to revise
or update any forward-looking statement to reflect events or circumstances
after the issuance of this press release.


SOURCE Sequenom, Inc.

Contact: Marcy Graham, Senior Director, Investor Relations & Corp Comm,
Sequenom, Inc., 858-202-9028,; Jakob Jakobsen, Media
Contact, Chandler Chicco Agency, 310-309-1003,
Press spacebar to pause and continue. Press esc to stop.